[Piperacillin in the therapy of severe bacterial infections: comparison of its efficacy and tolerance vs. ceftazidime].
38 patients with severe acute bacterial systemic infections have been enrolled in this study: 19 patients were treated with piperacillin (100-200 mg/kg/day) and 19 with ceftazidime (45-90 mg/kg/day) by i.v. route. In both groups monotherapy has been found effective and well tolerated. Serious side-effects have not been observed. The high cure and eradication rates in both groups do not show statistically significant differences (chi 2 = 0.620 and chi 2 = 0.219, respectively, p greater than 0.05).
D'Amato
C
C
Bordi
E
E
De Carlo
G
G
Puro
V
V
Visco
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004361:Drug Tolerance; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010878:Piperacillin / Q000008:administration & dosage / Q000627:therapeutic use*
D002442:Ceftazidime; D010878:Piperacillin
La piperacillina nella terapia delle infezioni batteriche gravi: confronto dell'efficacia e tollerabilità vs ceftazidime.